Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/first-patient-dosed-for-mrct-phase-3-study-on-first-line-ls-sclc-of-henlius-anti-pd-1-mab-serplulimab-in-europe-301967355.html
https://www.clinicaltrialsarena.com/news/shanghai-henlius-breast-cancer/
https://www.prnewswire.com/news-releases/astrum-005-the-first-immunotherapy-clinical-study-of-sclc-published-in-jama-one-of-the-top-medical-journals-in-the-world-301635462.html
https://www.centerforbiosimilars.com/view/henlius-pertuzumab-biosimilar-shows-similar-pk-profile-to-reference-product-in-first-human-study
https://www.prnewswire.com/news-releases/astrum-005-henlius-released-phase-3-study-results-for-the-first-line-treatment-of-small-cell-lung-cancer-of-serplulimab-at-asco-2022-301561541.html
https://www.prnewswire.com/news-releases/henlius-serplulimab-granted-orphan-drug-designation-in-the-united-states-for-small-cell-lung-cancer-301520127.html
https://www.prnewswire.com/news-releases/henlius-receives-nmpa-approval-for-its-first-innovative-monoclonal-antibody-hansizhuang-301510799.html